Medicines
Prosonix is the world leader in use of ultrasonic pharmaceutical particle engineering technologies for the manufacture of high value pharmaceutical powders and Making Better Medicines. Our pipeline addresses the fast-growing market sectors of asthma, COPD and other respiratory disorders, as well as niche opportunities in orally and parentally delivered products. Prosonix proprietary technologies can be used for API manufacture at any scale.
Particles
Prosonitron™, DISCUS®, UMAX®, SAX™ and PRT based process technologies are proprietary “Solution-to-Particle” methods for controlling crystal size, shape and polymorph for APIs, aimed at Making Better Medicines. Technologies offer dose-to-dose uniformity, formulation consistency, stability and 200% performance increase of inhaled APIs compared to micronized. Combination particles of multiple APIs can be manufactured.
Ultrasound
Power ultrasound facilitates controlled and reproducible crystal nucleation which is fundamental in controlling crystallization. Sonocrystallization delivers controlled nucleation and superior control of particle size, morphology, polymorphism, crystallinity and purity, and in doing so helps eliminate the need for troublesome external seeding and micronization for inhaled medicines.
SonoLab
Multipurpose laboratory equipment for sonocrystallization & sonochemistry are now available. These highly effective and flexible research tools facilitate 100ml – 100L operational capability in batch or continuous operation and can be integrated with automated laboratory reactors. The unique designs allow seamless transition and scale up to Prosonitron™ technology for commercial scale operation.
Prosonitron
Prosonix provide cGMP & ATEX sonocrystallization Prosonitron™ ultrasonic process and reactor technology. They are aligned with emergent FDA “QbD” and “Design for Intent” philosophy. Our proprietary systems are of modular design for optimum flexibility and are an easy retro-fit to existing equipment. They are proven across scale in API production and can be seen as sustainable green technology.
| September 1-3, 2010: The Science of Medicines, Nottingham, UK |
 |
 |
 |
| Written by Graham Ruecroft |
| Monday, 07 June 2010 00:00 |
|
For further details please refer to: http://www.ukpharmsci.org/Default.asp              |
| Last Updated on Wednesday, 18 August 2010 11:29 |
Prosonix CEO David Hipkiss and Senior Scientist Dr Dipesh Parikh will be presenting at the Academy of Pharmaceutical Sciences inaugural science conference UK-PharmSci 2010 entitled The Science of Medicines taking place 1-3 September 2010 at East Midlands Conference Centre, Nottingham, UK. This promises to be the premier conference for pharmaceutical scientists in the United Kingdom in 2010. David will talk about the Formulation of combination and triple drug therapies via inhaled route. Dipesh will present a poster from the podium entitled: Sonocrystallization Particle Engineering for Inhalable Medicines. The aims of the UK-PharmSci Conference 2010 are to showcase the best of pharmaceutical science from the UK and around the world bringing together academic and industrial institutions, providing state of the art technologies and a platform for the development of new pharmaceutical talent.
Latest News
Events
Prosonix Blog
Click here to visit the Prosonix Blog where Prosonix experts will post their thoughts on a regular basis. You can also submit your own content here and it will appear automatically in the blog following editor review.
Latest Blog Entries
Popular
Newsflash
| Prosonix is pleased to announce the launch of its UMAX® technology - an acronym for Ultrasound Mediated Amorphous to Crystalline transition - which is a new disruptive particle engineering technology set to revolutionise respiratory medicine. The proprietary technology has now been demonstrated on over 30 generic and novel drug molecules and combination products. |
Who's Online
Login Form
Prosonix RSS Resources
Prosonix Quick Search
ISO9000 accreditation
